During the past decade, Pharmatech Oncology Inc conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Pharmatech Oncology Inc" are "Metastatic Non-Small Cell Lung Cancer" (1 trials) and "Urothelial Carcinoma" (1 trials). Many other conditions were trialed in "Pharmatech Oncology Inc" in a lesser frequency.

Most popular intervention types in "Pharmatech Oncology Inc" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Ramucirumab" (2 trials), "Docetaxel" (1 trials), "Erlotinib" (1 trials) and "Gefitinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Pharmatech Oncology Inc" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Pharmatech Oncology Inc". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Pharmatech Oncology Inc, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Pharmatech Oncology Inc, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".